Recently, in a larger study including 203 stage IIIB/IV NSCLC patients, it was shown the complementary value of detecting ALK-rearranged CTCs during treatment with ALK inhibitors through serial blood sampling. Here, ALK is linked to non-small cell lung carcinoma.